Here is the sentence that costs brands the most money, and it is usually written by someone in marketing who meant well:

"Relieves arthritis knee pain."

Six words. The product did not change. The heating element did not change. The factory did not change. What changed is the regulatory category the product sits in — from a low-risk consumer product your brand can launch with a certificate file, to a regulated device you are now marketing without authorization. Claim language is the dial that moves a heated wrap across that line, and the dial turns in both directions.

This article is written from the supplier side of that line, which is an unusual place to write from. We are an ODM: LIGHT BDB develops heated wellness products and contracts their manufacture for other people's brands. We do not hold ISO 13485, we have no FDA approvals, and we do not write your claims. What we can do is tell you where the edges are, what to put on the box regardless of your positioning, and what to ask us for — so the compliance conversation happens in week one instead of after a retail buyer's legal team reads your packaging.

Not legal advice. Nothing here replaces a review by your own US regulatory counsel. Laws and FDA policy change; the guidance cited below is dated deliberately.

Why do wellness device marketing claims decide your FDA category?

Because US law defines a device by intended use, and intended use is established by what you say, not by what the product does.

Two heated knee wraps can be built on the same graphene far-infrared heating platform, from the same Panyu components and the same Shenzhen assembly line. One is sold as "warmth and comfort for cold-weather walks." The other is sold as a way to treat arthritis pain. The first may sit outside device requirements entirely under FDA's general wellness policy. The second is now intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease — the statutory definition of a device — and needs a premarket pathway the first one does not.

The same logic applies to light. Two near-identical near-infrared products, distinguished only by whether the marketing describes relaxation or a clinical outcome, can land in different regulatory buckets. The technology is a cost and compliance-input decision; the claim is a positioning decision. Brands routinely optimize the first and improvise the second.

The practical consequence: decide your claim envelope before you finalize the BOM. If your roadmap needs disease-adjacent language, that has to be designed in — different testing, different labeling, a different launch timeline — and a factory cannot retrofit it onto a finished SKU. For mechanism differences between conductive heat and light-based devices, see heating vs NIR.

What counts as a general wellness claim in 2026?

FDA's January 2026 guidance describes two acceptable general wellness intended uses, and keeps a low-risk requirement on top of both.

Branch one — no disease reference at all. The product is intended to maintain or encourage a healthy lifestyle, or to promote general health states such as relaxation, stress management, sleep management, physical fitness or mental acuity — without referring to any disease or condition. A heated eye massager sold for "unwinding before bed" lives here.

Branch two — disease-adjacent, but carefully framed. The product may reference a chronic disease only in the form of "may help reduce the risk of" or "may help people live well with" that condition, where the relationship between healthy-lifestyle choices and the condition is well understood and accepted. It is narrow, and it is not a licence to claim symptom relief.

On top of the intended use, the product must be low risk: non-invasive, non-implanted, and not using a technology that would pose a safety risk without specific regulatory controls. That last clause is the one to watch if your product involves light output.

Note the pattern. Every acceptable-left entry describes the product or the user's experience. Nearly every unacceptable-right entry describes a medical outcome. The rewrite is usually shorter than the original, and cheaper.

A brand in the sleep category built a heated eye massager with a beautiful unboxing and a claim on the insert card that it "helped treat insomnia." A large retailer's compliance team flagged the insert — not the device — three weeks before a scheduled launch. The fix took four minutes. Re-printing 12,000 insert cards did not.

Why is "FDA registered" not "FDA cleared"?

Because registration is a filing about a facility, and clearance is a review of a product for a specific intended use. The three phrases below get used interchangeably and should not be.

• FDA cleared — the product went through a premarket review such as 510(k) for a defined intended use. This is a product-level determination.
• FDA registered — the establishment is registered with FDA and products are listed. It does not mean the agency reviewed anything, and it does not make a product authorized. Any supplier implying otherwise is either confused or trading on your confusion.
• General wellness — low risk, with claims that avoid disease. FDA states it does not intend to enforce device premarket and postmarket requirements for products that fit this policy.

The WHOOP case is the cleanest recent illustration. On July 14, 2025, FDA issued a warning letter over a "Blood Pressure Insights" feature, describing the product as adulterated and misbranded because it was marketed without authorization: the agency's position was that estimating blood pressure is inherently associated with diagnosing hypotension and hypertension. WHOOP argued the feature was a wellness feature. FDA closed the letter after the feature and its labeling were changed. The hardware was never the issue; the framing was.

For a buyer, the takeaway is blunt: if a supplier markets a certification as proof that your product is authorized for a health claim, ask for the document that says so. We do not make that claim about ourselves. We are a wellness-device ODM: we do not hold ISO 13485, no product of ours is FDA approved, and none of our products is a medical device unless your own regulatory pathway makes it one. What we can hand you is the technical file and the per-model, per-market certificates.

Who else is watching — FTC and NAD, not just FDA?

FDA governs the label; the FTC governs the advertising, and it does not care which FDA category your product is in.

Under the two agencies' memorandum of understanding, FDA takes primary responsibility for claims on labeling and FTC for claims in advertising — and FTC has been explicit that this does not limit its jurisdiction over labeling claims either. More importantly for brands, the FTC's analysis does not distinguish between a food, a supplement or a device. A claim about a health benefit is a claim about a health benefit, and it requires competent and reliable scientific evidence.

The FTC's Health Products Compliance Guidance, issued in December 2022, replaced its 1998 dietary-supplement guide and extended those principles to all health-related products. Three points matter to a heated-product brand:

1. Implied claims count. Literally true phrases such as "clinically tested" or "cardiologist recommended" can convey a broader message than the words support — including through product names, imagery and before/after photography. Your packaging can be technically accurate and still misleading.
2. Substantiation is steep. For claims that a product can treat a disease or its symptoms, the FTC's expectation is generally well-designed randomized controlled human testing — a bar most consumer wellness brands cannot clear, which is itself an argument for staying on the wellness side of the line.
3. Remedies are recurring. The FTC has brought hundreds of health-related advertising cases and can require corrective advertising. The cost of an over-claim is not a fine; it is a re-education campaign about your own product.

The National Advertising Division (NAD) of BBB National Programs also reviews health-benefit claims through self-regulation: no legal penalty for losing, but the case is published, and it is public.

A sourcing lead at a California DTC brand wanted one line on the Amazon listing: "clinically tested." True — the brand had run an internal comfort study. The problem was what the phrase implied. The rewrite, "tested for comfort with 40 users over 14 days," was more specific, more persuasive, and defensible. Specificity is usually the cheapest fix available.

What does this mean for a heated wrap, belt or eye massager specifically?

The claim risk profile differs by product type, and the difference is worth designing around. For the category question underneath — whether heat or light is the right therapy to build a brand around — see heat therapy vs red light therapy.

Heat-only products — a heated knee wrap, a far-infrared abdominal heating belt, a lumbar belt. Mechanism is conductive warming, consumers understand it in one second, and the claim risk concentrates almost entirely in adjectives: "deep," "penetrating," "therapeutic," "healing." Strip those four words and most heat-only SKUs become straightforward general-wellness products.

Products with light. If your SKU includes NIR or red light, you inherit a light-safety review on top of the claim envelope, and the claim risk rises because the consumer story is inherently therapeutic-sounding. Any statement about cell-level effects is a disease-adjacent claim. For how the three light sources should be described on a box, see NIR vs red light vs full spectrum.

Products with air pressure or vibration — a heated eye massager, an airbag lumbar belt. Usually positioned as massage devices, which is a comfortable shelf. But "relieves" plus a symptom name pulls them back across the line, whichever module is doing the work.

The two most common mistakes our buyers make: using "therapeutic" as a general adjective, which reads as a medical intended use, and naming a symptom in a product title, where it is hardest to walk back. For the format-level version of this question — cordless versus plug-in, wrap versus strap-on — see cordless vs plug-in heated wraps.

What must appear on the box regardless of your claims?

Five things that have nothing to do with marketing and everything to do with getting through customs and into retail.

• Country of origin marking, in the form US Customs expects on the article and its container. See country of origin labeling rules.
• Electrical safety marks for the destination market — the certificate set is per model and per market, not per factory.
• Battery transport documentation — UN38.3 test summary and MSDS — if the product ships with lithium cells.
• California Proposition 65 warning content if your product or packaging is in scope. See Prop 65 labeling.
• Instruction manual language and warning statements, matched to the market. A US retailer will reject a manual that is English-only-by-accident, meaning translated but unreviewed.

If your product also streams audio or contains a radio, FCC marking joins the list — see FCC marking for light and sound devices. And if you are selling into Europe, RoHS and REACH sit alongside: RoHS and REACH compliance.

What should you ask your OEM to hand over before launch?

Four documents per SKU, and a clear statement of who owns claim review.

1. Certificates and test reports by model and market — holder's legal name, validity dates, listed model numbers.
2. The technical file — heating-element specification, power source, temperature limits, over-temperature protection behavior.
3. Battery documentation — UN38.3 summary and MSDS, where applicable.
4. A written statement of what the factory does and does not certify. Ours reads: wellness devices, no medical quality-system certification, no premarket regulatory review, UL status is a plant registration rather than a product listing.

Stating that in writing is unusual, and it is the point. A supplier that will not name the edge of what it holds is asking you to discover the edge later — usually in front of a retail buyer. The full method for reading these documents is in how to read a test report and confirm it covers your SKU, and our certificate matrix by plant is on facilities.

Then assign the claim review. In every OEM/ODM relationship we know of, claim review belongs to the brand, not the factory: your counsel, your market, your legal exposure. What the factory owes you is the technical evidence underneath the claim. How much compliance work sits behind that claim also depends on your route to market — channel compliance compares Amazon FBA with direct-to-retail.

What are the honest trade-offs of going the general-wellness route?

Three, and they are real. This is a trade, not a free win.

You lose the strongest marketing story in the category. Competitors willing to write "relieves arthritis pain" will out-convert you in a cold-ads test. Some of them are also one warning letter away from a mandated corrective-advertising campaign — and the ones who are not are usually the ones who already did this work.

We cannot do the claim review for you. We supply documents; we do not opine on your market access. If you need a regulated medical pathway, we are the wrong factory — say so early and we will tell you the same thing.

Our certification stack has a defined ceiling. ISO 9001, ISO 14001, amfori BSCI, UL registered factory, Sony Green Partner, plus product-level CE / FCC / PSE / UL per model and market. That is enough for general wellness and retail compliance in the US, EU and Japan, and it is not a medical quality system. We do not hold ISO 13485 and we do not intend to imply otherwise.

One more: the line moves. FDA's wellness guidance was updated in January 2026, in part because of the WHOOP dispute, and it will be updated again. Any compliance position you build should be reviewable, not permanent.

If you want the technical side of this conversation — what we can certify, per model, per market — start an RFQ or write to serina@lightbdb.com.